Neuren Pharmaceuticals (ASX: NEU) — Company Overview, News & Financial Data
Neuren Pharmaceuticals is an Australian pharmaceutical company developing CNS disorder treatments.
Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapies for serious neurodevelopmental disorders and neurological conditions caused by genetic abnormalities or brain injuries. Headquartered in Hawthorn East, Victoria, Australia, and incorporated in New Zealand, the company focuses on conditions with limited or no approved treatment options. Its lead commercialized product, trofinetide, is licensed globally to Acadia Pharmaceuticals for the treatment of Rett syndrome. Neuren is also advancing its proprietary drug candidate NNZ-2591 through clinical development for multiple rare neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt-Hopkins syndrome, Angelman syndrome, and Dup15q syndrome.
Snapshot
Operations
Products and/or services of Neuren Pharmaceuticals
- Commercial Licensing Agreements: Primary revenue generation through exclusive international licensing partnerships for commercialized pharmaceutical therapies, providing ongoing royalty streams from end-market sales alongside contractually structured regulatory and commercial performance milestone payments across global healthcare markets.
- Trofinetide Therapeutics: Commercial-stage oral pharmaceutical treatments formulated as synthetic analogs of cyclic glycine-proline, approved for treating pediatric and adult patients diagnosed with Rett syndrome, generating significant royalty income from licensed global pharmaceutical distribution networks.
- Phelan-McDermid Syndrome Clinical Development: Mid-stage clinical development of proprietary oral drug candidates designed to restore synaptic function and reduce neuroinflammation in patients with Phelan-McDermid syndrome, addressing severe genetic neurodevelopmental impairments without prior approved treatment options.
- Pitt Hopkins Syndrome Clinical Development: Phase two clinical evaluation of novel synthetic neuroprotective therapies targeting genetic mutations responsible for Pitt Hopkins syndrome, aiming to alleviate significant motor dysfunction, cognitive impairment, hyperventilation, and gastrointestinal complications in affected individuals.
- Angelman Syndrome Clinical Development: Targeted clinical trial programs evaluating oral small-molecule candidates for Angelman syndrome, focusing on restoring key synaptic signaling mechanisms to improve motor control, speech capabilities, and severe sleep disturbances associated with maternal gene loss.
- Hypoxic-Ischemic Encephalopathy Therapeutics: Preclinical and clinical investigation of neuroprotective drug candidates designed to treat brain injury resulting from acute oxygen deprivation in newborn infants, mitigating long-term neurological damage through targeted biological mechanisms in neonatal care.
Neuren Pharmaceuticals executive team
- Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A.CEO, MD & Executive Director
- Ms. Lauren Frazer C.A.CFO & Company Secretary
- Dr. Clive Blower BSc (Hons), Ph.D.Chief Operations Officer
- Mr. Lawrence Glass BA (Biology)Chief Science Officer
- Mr. Gerry ZhaoChief Business Officer
- Dr. Liza A. Squires M.D.Chief Medical Officer
- Mr. Daryl DekarskeChief Regulatory Officer